AI Terminal
ROQUEFORT THERAPEUTICS PLC
Director's Dealing • Dec 4, 2024
5061_dirs_2024-12-04_a9efc308-2b12-4b6d-a06a-f303469e262a.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 8386O
Roquefort Therapeutics PLC
04 December 2024
4 December 2024
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director Share Distribution
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets , has been advised by VG Corporate Trustee Limited that an employee benefit trust (unrelated to the Company), has been terminated and the trust assets have been distributed to the beneficiaries. As a result of the trust distribution, three Directors of the Company (Ajan Reginald, Dr Darrin Disley and Sir Marin Evans) have received ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed below:
| Director | Number of Ordinary Shares Received for Nil Consideration | Number of Ordinary Shares Now Held | % of Company's Issued Capital |
| Ajan Reginald | 34,432 | 12,346,413 | 9.1% |
| Dr Darrin Disley | 9,146 | 2,024,196 | 1.5% |
| Sir Martin Evans | 2,690 | 2,690 | 0.0% |
-ENDS-
Enquiries:
| Roquefort Therapeutics plc | +44 (0)20 3918 8633 |
| Stephen West (Chairman) / Ajan Reginald (CEO) | |
| SP Angel Corporate Finance LLP (Broker) David Hignell / Vadim Alexandre / Devik Mehta |
+44 (0) 20 3470 0470 |
| Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale |
+44 (0)20 7466 5000 |
| Peak IR (Investor Relations) Seb Wykeham |
+33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immunology and oncology markets prior to partnering with big pharma.
Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· Midkine mRNA therapeutics with novel anti-cancer approach;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK cell-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).
This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Ajan Reginald | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 |
|
| b) | Nature of the transaction | Trust distribution of 34,432 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 0 pence per share | 34,432 | ||
| d | Aggregated information - Aggregated volume - Price |
- 34,432 - 0p |
|
| e) | Date of the transactions | 3 December 2024 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market |
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Darrin Disley | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 |
|
| b) | Nature of the transaction | Trust distribution of 9,146 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 0 pence per share | 9,146 | ||
| d | Aggregated information - Aggregated volume - Price |
- 9,146 - 0p |
|
| e) | Date of the transactions | 3 December 2024 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market |
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Sir Martin Evans | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.01 par value ISIN: GB00BMDQ2T15 |
|
| b) | Nature of the transaction | Trust distribution of 2,690 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 0 pence per share | 2,690 | ||
| d | Aggregated information - Aggregated volume - Price |
- 2,690 - 0p |
|
| e) | Date of the transactions | 3 December 2024 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGZMGZDDFGDZM